Vigonvita Life Sciences Co., Ltd.

苏州旺山旺水生物医药股份有限公司

02630.HK

Biopharmaceutical company discovering, developing and commercializing small-molecule drugs focused on neuropsychiatry and reproductive health, with core product candidates LV232 for major depressive disorder and TPN171 for erectile dysfunction, plus four clinical-stage and three pre-clinical candidates.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Connected or related major customers / suppliers
• Distribution model
• Reliance on platforms, partners or licences
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Particular sales arrangements
• Capacity and utilisation
• Decline in revenue or profit
• Negative operating cash flow
• Cash burn and runway
• Goodwill, intangibles and asset impairment
• Adverse change after the track record
• Related-party transactions and balances
• Material share-based payments
• Chapter 18A biotech